ArticleJCI insight2025

Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma.

Sixuan Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.